Updates are available Correction dated 2023-03-24
Click to view Correction: https://doi.org/10.1186/s13023-023-02659-9
-
Authors
Koto, Yuta
Narita, Aya
Noto, Shinichi
Ono, Midori
Hamada, Anna Lissa
Sakai, Norio https://orcid.org/0000-0003-3374-6709
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company
- License Information
-
More Information
Article History
Received: 14 March 2022
Accepted: 30 June 2022
First Online: 19 July 2022
Change Date: 24 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13023-023-02659-9
Declarations
:
: The protocol and informed consent form were approved on January 13, 2021 (No. 20342) by Osaka University Clinical Research Review Committee. Written informed consent was obtained by patients or their proxies. This study was conducted in accordance with the protocol, the Declaration of Helsinki, Guidelines for Good Pharmacoepidemiology Practices by the International Society of Pharmacoepidemiology, and Japanese regulations.
: Not applicable.
: YK, AN, and NS have received research funding from Takeda Pharmaceutical Company Limited (Takeda, hereafter) and have served as consultants and on speakers’ bureaus for Takeda. SN has served as a consultant for Takeda. MO and ALH are employees of Takeda and MO is a stockholder of Takeda.
